.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Pneumonia remains a leading cause of morbidity and mortality worldwide, especially in severe cases requiring intensive care. Consequently, clinicians need precise tools for early risk stratification. Recent evidence highlights the significant role of thrombosis biomarkers in pneumonia as diagnostic and prognostic indicators. These markers reflect the complex interplay between infection, inflammation, and the coagulation system. Specifically, thrombin-antithrombin complex (TAT), plasmin-alpha2-plasmin inhibitor complex (PIC), soluble thrombomodulin (sTM), and tissue plasminogen activator-inhibitor complex (t-PAI·C) serve as valuable indicators of disease severity.
Researchers recently evaluated 414 patients to determine the performance of these automated biomarkers. Notably, sTM and t-PAI·C demonstrated exceptional diagnostic accuracy. The study recorded area under the curve (AUC) values of 0.887 for sTM and 0.892 for t-PAI·C in identifying severe pneumonia. Furthermore, TAT and PIC also showed strong performance, with AUC values of 0.811 and 0.771, respectively. These findings suggest that monitoring these biomarkers can facilitate earlier identification of patients progressing toward severe respiratory failure.
Predicting the clinical trajectory of pneumonia is vital for timely intervention. In addition to diagnosis, these markers provide critical prognostic insights. For instance, sTM and t-PAI·C effectively predicted patient outcomes with AUC values of 0.840 and 0.811. Higher levels of these biomarkers correlate with increased endothelial damage and fibrinolysis inhibition. Therefore, integrating these tests into routine diagnostic panels could help critical care teams prioritize high-risk patients. Moreover, the automation of these chemiluminescence immunoassays ensures faster turnaround times in emergency settings.
Implementation of these markers helps bridge the gap between traditional laboratory tests and clinical bedside assessment. While procalcitonin and C-reactive protein remain standard, they do not directly assess coagulopathy. Conversely, thrombosis biomarkers in pneumonia offer a direct view of vascular and hemostatic stress. This multi-marker approach significantly improves the sensitivity of severity scores. Indeed, clinicians can now leverage these automation technologies to refine their treatment strategies for severe pneumonia patients.
The most effective biomarkers identified for diagnosis are soluble thrombomodulin (sTM) and tissue plasminogen activator-inhibitor complex (t-PAI·C), which show high diagnostic accuracy.
Elevated levels of markers like sTM and t-PAI·C reflect significant endothelial injury and impaired fibrinolysis, which are strongly associated with poor clinical outcomes and mortality.
The study utilized automated chemiluminescence immunoassays on high-throughput analyzers, making it a feasible addition to modern hospital laboratories.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Fan Y et al. Thrombosis biomarkers: utility in early diagnosis and prognosis of severe pneumonia. Thromb J. 2026 May 29. doi: 10.1186/s12959-026-00876-3. PMID: 42216223.
2. Zhang J et al. Identification of soluble thrombomodulin and tissue plasminogen activator-inhibitor complex as biomarkers for prognosis and early evaluation of septic shock and sepsis-induced disseminated intravascular coagulation. Ann Palliat Med. 2021;10(10):10170-10184.
3. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38-44.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This study explores the utility of TAT, PIC, sTM, and t-PAI·C biomarkers in diagnosing and predicting outcomes for patients with severe pneumonia....
3 months ago
A large NHANES cohort study reveals that higher Healthy Eating Index scores significantly reduce all-cause mortality risk in CKD patients by 45%. This analysis highlights the importance of comprehensive diet quality and medical nutrition therapy in renal care to optimize long-term clinical survival.
Today
A prospective cohort study demonstrates that poor adolescent sleep quality, especially long sleep latency and reduced efficiency, increases dysmenorrhea severity in young adulthood. Addressing adolescent rest patterns offers a critical preventive avenue for clinicians.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Today
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
